Q-omics provides the consensus-scored SUGT1-DT profile across patient tissues and cancer cell-line models. SUGT1-DT expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SUGT1-DT is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, SUGT1-DT RNA expression shows 16,826 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where SUGT1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUGT1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUGT1-DT survival associations across molecular data types. SUGT1-DT RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUGT1-DT RNA expression–survival associations across cancer types. High SUGT1-DT expression shows unfavorable associations in KIRC, ACC, UVM and ESCA, but favorable associations in BLCA and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SUGT1-DT RNA expression.
This table summarizes SUGT1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for SUGT1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUGT1-DT shows higher tumor expression in BLCA, COAD, HNSC, LIHC, STAD and UCEC. The BLCA box plot shows higher SUGT1-DT RNA expression in tumor versus normal tissue (log2 FC = +1.008, t-test p < 0.001).
This table shows molecular features associated with SUGT1-DT in patient tissues and cancer cell lines. In patient samples, SUGT1-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
